H.C. Wainwright downgraded aTyr Pharma (ATYR) to Neutral from Buy without a price target after the company’s Phase 3 EFZO-FIT study evaluating lead asset efzofitimod for the treatment of pulmonary sarcoidosis missed the primary endpoint. “Many open questions remain regarding a path forward,” the analyst tells investors in a research note. The firm cites the lack of regulatory visibility for the downgrade.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- aTyr Pharma downgraded to Market Perform from Outperform at Leerink
- aTyr Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
- Why Is Atyr Pharma Stock Down Today?
- Buy Rating for aTyr Pharma Despite Phase 3 Trial Setback, Focus on Quality of Life Improvements
- Leerink sees low chance of aTyr advancing efzofitimod after miss